arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

HCW Biologics Inc.

HCWB
$1.68 ▼ -0.15 (-8.20%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

HCW Biologics Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $2.2M
Dividend Yield
Revenue Growth 1758.5%
Op. Margin None
ROIC -42.6%
FCF / Share $-2.99
Trailing P/E
Price / Book 0.3x
FCF Yield
Debt / Equity 0.88
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$121.73K
↑ +1758.5%
Net Income Profit after all expenses
$3.47M
— 0.0%
Operating Margin Operating profit as % of sales
49.8%
↑ +122.4%
FCF / Share Free cash flow per share
$-2.99
↓ -928.7%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
0
Financial Health
18
Cash Quality
83

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters